TG Therapeutics Inc (NASDAQ:TGTX) currently has a daily average trading volume of 3.15M but it saw 1276299 shares traded in last market. With a market cap of 5.58B USD, the company’s current market price of $35.14 came falling about -0.28 while comparing to the previous closing price of $35.24. In past 52 weeks, the stock remained buoying in the range of price level as high as $46.48 and as low as $15.16. In the recent trading on the day, stock has struck highest price mark of $34.8001 while lowest mark touched by it was $35.79.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the TD Cowen which initiated the stock as “Buy” in its note to investors issued on October 29, 2024, recommending a price target of $50 for it. Goldman upgraded its recommendation for the stock as a “Neutral” from “Sell” on August 02, 2023 while assigning a price target range of $16-$12. Jefferies issued its recommendations for the stock as it resumed the price target for the stock in the range of between $55 and $40.
Over the week, TGTX’s stock price is moving -0.93% down while it is -16.39% when we observe its performance for the past one month. Year-to-date it is 16.74% up and over the past year, the stock is showing an upside performance of 106.95%.
The company is expected to be releasing its next quarterly report on 2025-May-04, for which analysts forecasted an EPS of 0.3 while estimate for next year EPS is 0.95. In next quarter, company is expected to be making quarterly sales of $153.05M as analysts are expecting the sales for current fiscal year at $596.09M and seeing the company making $824.6M in sales next year. Moreover, analysts are in estimates of $147.76M for current-quarter revenue.
Currently, TG Therapeutics Inc’s total number of outstanding shares is 158.17M with 9.70% of that held by the insiders while 63.22% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 7.99% and return on equity (ROE) at 19.70%. It has a price to earnings ratio (P/E ratio) of 144.02 while having a 19.71 of forward P/E ratio. Stock’s beta reads 1.93. Stock has a price to book (P/B) ratio of 23.42 while price to sale or P/S ratio amounts to 14.44. Its return on asset (ROA) is 7.60% on average.
